Tafamidis ATTR denied for failing step therapy by Humana?

Humana's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy for Tafamidis (ATTR Amyloidosis) — and Why This Is Often Incorrectly Applied

Step-therapy (also called "fail-first") denials for tafamidis are among the most legally vulnerable denial types for this condition. ATTR amyloidosis is a rare, progressive disease with a limited treatment landscape. Unlike many conditions where multiple comparable agents exist, the pharmacological options for ATTR-specific disease stabilization are narrow. When Humana's step-therapy protocol requires a patient to try and fail an alternative agent before accessing tafamidis, the appeal should focus on: (1) whether the required step agents are actually indicated for ATTR amyloidosis and (2) whether the patient has already tried them, making the step requirement already satisfied.

Many states have enacted step-therapy override laws requiring insurers to grant exceptions when step therapy is clinically inappropriate, has already been attempted, or would cause harm. Check whether your state's law applies to your plan type.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Step-therapy denials are adverse benefit determinations. You have the right to a full internal appeal with access to the specific clinical criteria used.
• Step-therapy exception request: Many states and some federal regulations require plans to have a formal step-therapy exception process. File this alongside or before the internal appeal.
• External review: After exhausting internal remedies, request IRO review. The IRO is not bound by Humana's step criteria — it applies independent clinical standards. Federal law provides approximately four months to request external review.
• Expedited track: Available when waiting poses health risk.

## Documentation to Gather

1. Prior treatment history with outcomes — document every prior therapy attempted for ATTR amyloidosis, with start/stop dates and the reason it was discontinued or deemed inadequate. 2. Clinical inappropriateness statement — if the required step agents are not indicated for ATTR amyloidosis or are contraindicated for your patient, your prescriber should state this explicitly (without asserting general contraindication facts — state it specific to this patient based on the chart). 3. Applicable guideline support — ask your cardiologist to reference current ACC/AHA or applicable cardiology guideline organization positions on the appropriate treatment sequence for ATTR amyloidosis. 4. Prescriber medical-necessity letter — explain why delay to complete step therapy poses a material clinical risk given the progressive nature of ATTR amyloidosis. 5. Humana's step-therapy protocol — request the exact required steps in writing and address each one explicitly.

## Criteria-Mapping Structure

| Humana Step Requirement | Chart Response | |---|---| | Required Step 1 agent | [Tried on date X, discontinued because Y] or [Not indicated for this patient because Z] | | Required Step 2 agent | [Same format] | | Exception criteria | [Cite applicable state step-therapy override law if applicable] |

A well-organized step-therapy appeal that maps each required step to a chart-documented outcome is one of the most consistently successful appeal types.